Compare Inovio Pharmaceuticals Inc (INO) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Sezzle Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Sezzle Inc trades at $176.11 (market cap $5.78B). The key difference: Sezzle Inc is far larger — about 64.7× Inovio Pharmaceuticals Inc's market cap, and Sezzle Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SEZL | |
|---|---|---|
Market Cap | $89.27M | $5.78B |
Sector | Health | Technology |
52-Week High | $2.87 | $188.55 |
52-Week Low | $1.05 | $50.97 |
Enterprise Value | $60.28M | $5.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Sezzle (SEZL) trades at $171.76, down 1.67% today but maintaining strong momentum with consistent earnings beats and bullish technical indicators. The stock shows robust fundamentals with 30.83% net income margin and 91.95% ROE, though valuations remain elevated at P/E 41.72. Recent news highlights product expansion and strong Q1 2026 results, with the company scheduled to report Q2 earnings on August 6, 2026.
Outlook remains positive given earnings momentum and analyst consensus, but high valuation multiples and competitive fintech landscape pose risks. The stock trades above the $162 consensus target, suggesting near-term consolidation potential before potential upward revisions post-earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
